Archive

ASH 2015: Early findings on oral therapies for relapsed/refractory DLBCL unveiled

by Thomas R. Collins: Early results show that venetoclax, a BCL-2-inhibitor, produced relatively good response rates in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.1

ASH 2015: Risk profile key in transplant decisions in non-Hodgkin lymphoma

by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.

ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

ASH 2015: Brentuximab vedotin data shows durable CR five years on – is this cure? Dr Robert Chen, (City of Hope, Duarte, CA, USA) discusses the five year survival data presented at ASH; who of the CR patients to watch and wait and who to go onto allo-SCT; and whether these patients are now cured. Click video image to view.

by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.

ASH 2015: Prognostic score helps assess chances of progression-free survival in HL autologous transplant recipients

by Thomas R. Collins: Researchers have developed a prognostic “score” to gauge the chances of progression-free survival in patients with relapsed or refractory Hodgkin lymphoma who have had… read more.

ASH 2015: Highlights of the 57th American Hematological Society Meeting. Professor Ajay Gopal (Seattle Cancer Care Alliance), Professor Stephen Ansell (Mayo Clinic), Professor John Sweetenham (Huntsman Cancer Institute) and Professor Joseph Connors (Vancouver) share their highlights of a very busy ASH and New Year’s resolutions for their management of lymphoma in 2016. Click video image to view.

ESOT 2015: Tailor-made immunosuppression and post-transplant follow-up

by Maria Dalby: Advances in diagnostic techniques, genetic testing and immunosuppressive protocols allow clinicians to tailor interventions to the individual patient’s needs to a greater extent than in… read more.

IMV 2015: Newly diagnosed multiple myeloma, elderly patients: Professor Gareth Morgan, (Little Rock, USA) and Professor Paul Richardson, (Boston, USA) discuss managing older patients with MM

The majority of patients presenting with MM are elderly and pose a considerable clinical challenge in terms of disease burden and comorbidities compared with their younger counterparts. A… read more.

ICML 2015 Poster Session: Healthcare utilisation in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post-ASCT

Vijayveer Bonthapally et al, Cambridge, MA, USA  / by Maria Dalby.  AETHERA is a randomised, placebo-controlled phase III study to evaluate whether consolidation treatment with brentuximab vedotin can… read more.

ICML 2015 Poster Session: Hodgkin lymphoma: PET-CT or bone marrow biopsy?

Zeinab Ali Abou Yehia et al, Houston, TX, USA / by Maria Dalby.  PET-CT scans appear to be more sensitive than bone marrow biopsies for detecting bone marrow… read more.

ICML 2015 Report: Thirty years of progress in cutaneous lymphoma research

John Ultmann Memorial Lecture / by Maria Dalby.  Cutaneous lymphomas are rare conditions that require careful linking of clinical features with pathological findings for accurate diagnoses and effective… read more.

ICML 2015 Report: Update on the revision of the WHO lymphoma classification

Steven H Swerdlow, University of Pittsburgh Medical Center, USA, / by Maria Dalby.  Knowledge is evolving fast in the field of lymphoma and the 2008 World Health Organization… read more.